Cell therapy trial for infection-related septic shock in ICU
Part of Infections clinical trials.
This Phase 2 trial tests an immune-boosting cell therapy (umbilical mesenchymal stromal cells) in people with septic shock—when infection causes dangerous stress on the heart and other organs. The goal is to see if this treatment can improve outcomes compared with standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You are in the ICU for the first time for this illness
- Your heart/blood pressure failure from infection has lasted at least 1 hour and needs strong blood-pressure medicine
- Within about a day, you also have at least one other new serious organ problem (lungs, blood, kidneys, or poor circulation measured by lactate)
- A clinician believes the shock is caused by infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment made from human umbilical cord cells to help the body fight severe infections (sepsis). It might reduce inflammation and improve recovery.
This trial tests whether a blood filtering treatment called hemoadsorption can help protect blood vessels in people with septic shock. It may be an option for patients who are already on strong blood pressure medications and steroids.
This trial looks at how the immune system changes after septic shock in adults in the ICU. It may help doctors better predict or manage complications by studying blood markers a few days after starting treatment.
This trial tests a special blood-filtering method (adaptive blood purification) for people with septic shock caused by a severe infection. It aims to see if this treatment can help control inflammation and improve recovery in the ICU.
This trial tests if a special fluid given through a vein can protect and repair the lining of your blood vessels during sepsis. Sepsis is a dangerous reaction to an infection that can damage organs. This study aims to see if this treatment helps patients in the intensive care unit (ICU) recover better.
This trial tests a new blood-cleansing device (HemoSystem REBOOT) that may help people with sepsis by removing harmful substances and improving immune function. It is for critically ill patients whose immune systems remain suppressed despite standard sepsis treatment.
Hear when a new Septic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.